2025年6月17日，非货币类ETF合计成交2371.73亿元，其中有46只ETF成交额破10亿元。 截至今日收盘，短融ETF、政金债券ETF、上证公司债ETF成交额居市场前列，分别达176.75亿、120.26 亿、102.97亿。行业主题类ETF仅1只：港股创新药ETF。 截至今日收盘，港股医疗ETF、基准国债ETF、港股创新药ETF基金换手率居市场前列，分别达 585.68%、382.54%、177.66%。行业主题类ETF共计7只，分别是港股医疗ETF、港股创新药ETF基金、 恒生医疗ETF基金、恒生创新药ETF、恒生创新药ETF、港股通医药ETF、港股创新药ETF。 短融ETF(511360.SH)最新份额规模达4.26亿。该产品紧密跟踪中证短融指数，中证短融指数从银行间市 场上市的债券中，选取投资级短融作为指数样本，以反映相应评级短融的整体表现。 该ETF全天成交额较前一交易日增长24.67%，明显放量。该ETF近5日日均成交额为130.72亿，近20日日 均成交额90.08亿，近期明显放量。该ETF当日换手率较前交易日增长27.19%。该ETF近5日和近20日日 均换手率分别为27.14%、19 ...

Core Viewpoint - The Hong Kong Innovative Drug ETF (159570) is experiencing significant inflows and growth, driven by a favorable market environment and accelerated clinical trial approvals for innovative drugs in China [1][3]. Group 1: Market Performance - The Hong Kong Innovative Drug ETF (159570) rose over 1%, with a trading volume exceeding 800 million yuan, leading its peers in scale and liquidity [1]. - The ETF has attracted a net inflow of nearly 140 million yuan in a single day, accumulating over 2.2 billion yuan in the last ten days, with a total size surpassing 6.4 billion yuan [1]. Group 2: Regulatory Developments - The National Medical Products Administration (NMPA) has announced a new 30-day approval process for innovative drug clinical trials, aimed at supporting key national research projects and encouraging global early-stage and multi-center clinical trials [3]. - The average time from application to approval for innovative drugs in China has been reduced by 57 days compared to other drugs, with priority-reviewed innovative drugs seeing an even greater reduction of 189 days [6]. Group 3: AI in Drug Development - A domestic innovative drug company has entered a strategic research collaboration with a global multinational corporation (MNC) focused on AI drug development, involving an upfront payment of 110 million USD and potential milestone payments totaling up to 16.2 billion USD [4]. - The trend of MNCs actively engaging in AI collaborations is accelerating, with over 30 partnerships in the AI drug development space in 2023, valued at approximately 10 billion USD [4]. Group 4: Domestic Innovative Drug Market Growth - The total value of domestic innovative drug business development (BD) transactions is projected to rise from 9.2 billion USD in 2020 to 52.3 billion USD by 2024, with upfront payments increasing from 600 million USD to 4.1 billion USD in the same period [5]. - The share of innovative drugs in China's core hospital market is expected to grow from 21% in 2015 to 29% by 2024, driven by policy improvements and market demand [12]. Group 5: Policy Support for Innovative Drugs - Since 2015, a series of healthcare reform policies have been implemented to facilitate the transition from generic to innovative drugs in China, including expedited drug approval processes and improved resource allocation [5][14]. - The entry of innovative drugs into the medical insurance directory has accelerated, with nearly 90% of successfully negotiated innovative drugs entering the directory within two years of approval from 2021 to 2024, compared to only 43% in 2019 [9].

东莞证券指出，随着药品审评审批制度改革深化、医保动态调整机制完善，行业创新生态显著优化，标 志着我国医药创新正式进入"量质齐升"的成果兑现期，产业竞争力向全球价值链高端迈进。 中邮证券则坚定看好2-3年维度的创新药行情。首先是出海，较多优质项目BD虽已有一定市场预期，但 仍存在落地超预期的可能，且海外估值并未泡沫化，出海也已形成正向循环，未来全球看国内创新药比 例仍有提升空间；其次资金面目前宽基对创新药板块的配置远未见顶，且外资对港股创新药的配置也有 提升空间。 产业链和公司方面，据方正证券表示， 据人民财讯6月16日报道，国家药监局综合司公开征求《关于优化创新药临床试验审评审批有关事项的 公告（征求意见稿）》意见。 其中意见提出对符合要求的创新药临床试验申请在30个工作日（通常是60天）内完成审评审批。 今年年初政府工作报告涉及了多项医药行业重点政策，强调对创新药的支持力度显著提升。 1）仿转创企业的创新重估，仿转创企业大多已穿越集采周期影响，创新成果不断涌现，估值应当重 估，核心：华纳药厂、三生制药、石药集团/新诺威、中国生物制药、翰森制药、康哲药业、先声药 业、远大医药、舒泰神、一品红等； 2）强者恒强 ...

Summary of the Conference Call for Innovent Biologics Company Overview - **Company**: Innovent Biologics - **Industry**: Innovative Pharmaceuticals Key Points and Arguments Industry Dynamics - The innovative drug sector is experiencing a rebound driven by changes in demand and policy, with Hong Kong's innovative drug sector valuations rising, albeit limited by profit growth [2][3] - The sector is at a historical low valuation, with recent data from the ASCO conference showcasing the global competitiveness of domestic innovative drug companies [3] Financial Performance - Innovent Biologics reported strong revenue performance, with projected revenue exceeding 8.2 billion yuan in 2024, representing a 40% year-on-year growth [2][6] - Q4 product revenue is expected to surpass 2 billion yuan, showing a 25% increase year-on-year [2][6] Product Pipeline and Commercialization - The company anticipates commercializing 14 products within the next one to two years, with several entering NDA and NMPA reviews or critical clinical studies [2][7] - Expected new revenue streams from products like IGF-1R and peptide I23P19 are projected to help achieve EBITDA breakeven by 2025, with domestic product revenue reaching 20 billion yuan by 2027 [2][7] Key Products and Innovations - The PD-1/IL-2 fusion protein IBI363 has shown significant efficacy in treating IO-resistant non-small cell lung cancer and third-line colorectal cancer, with global peak sales potential estimated at 10 billion USD [2][9][10] - The drug's design enhances efficacy while reducing toxicity, showing promising data in clinical trials [9][10] Market Opportunities - The GIP/GLP-1 dual receptor agonist, Masitide, is expected to be approved by 2025, providing a new growth avenue for the company [4][12] - Innovent's comprehensive layout in the metabolic field, including the P9 monoclonal antibody, is expected to drive sales growth [4][13] Competitive Landscape - The company is well-positioned in the autoimmune sector with innovative drugs like IL-23 P19, which is anticipated to gain market approval soon [4][16] - The market for thyroid eye disease is significant, with approximately 4 million patients in China, and Innovent's IGF-1R antibody showing promising results [14] Valuation and Future Outlook - Innovent's projected revenue of 20 billion yuan by 2027 is seen as a target, with potential peak sales reaching 30 billion yuan based on ongoing clinical developments [8] - The company is suitable for DCF valuation rather than PS, as its early-stage assets have not been fully assessed [8] - The future outlook remains optimistic, with numerous catalysts expected from clinical data releases in the coming years [18] Conclusion - Innovent Biologics is positioned as a strong candidate for medium to long-term investment, supported by robust revenue growth, a promising product pipeline, and favorable market dynamics [18]

Core Insights - The pharmaceutical industry in China is undergoing a significant transformation from a focus on generic drugs to innovation-driven development, particularly in mRNA technology and other advanced therapies [1][4][10] - The traditional model of "using generics to support innovation" is becoming unsustainable as over 60% of generic drug companies have seen profit margins fall below critical levels [1][4] - Major players like Heng Rui and others are adapting by streamlining operations and focusing on innovative drug development to maintain competitiveness in a rapidly evolving market [5][10] Company-Specific Developments - Heng Rui Pharmaceutical is investing in mRNA production lines to support clinical trials for cancer vaccines, indicating a strategic shift towards cutting-edge technology [1] - The company has seen its market capitalization drop from over 610 billion RMB in 2020 to approximately 355.2 billion RMB in 2025, reflecting the challenges posed by national drug procurement policies [3] - Heng Rui has reduced its sales team from 17,138 in 2020 to 8,910 by 2024, a decrease of about 48%, as part of its restructuring efforts [5] Industry Trends - The implementation of national drug procurement policies has significantly impacted profit margins for traditional pharmaceutical companies, forcing them to innovate or face decline [4][10] - The market is witnessing a shift where innovative drug companies are gaining market share, with companies like Innovent Biologics and others achieving substantial valuations [8][9] - The total value of out-licensing deals for innovative drugs in China reached approximately 36.9 billion USD in early 2025, indicating a robust market for innovative therapies [8] Future Outlook - The industry is expected to see increased consolidation, with a focus on high-value innovative drugs while low-margin generic drugs may be phased out [10][12] - Companies are encouraged to adopt a "dual-platform strategy," maintaining generics for cash flow while developing innovative drug platforms to attract investment [10][11] - The integration of AI technology in drug development is anticipated to accelerate the process and reduce costs, further enhancing the competitive landscape [15][16]

Investment Rating - Initiate with OUTPERFORM rating [1][2] Core Views - Hansoh Pharma is a leading innovative pharmaceutical company in China, focusing on oncology, anti-infection, central nervous system diseases, metabolic diseases, and autoimmune diseases, with a robust pipeline of over 30 clinical-stage innovative drug projects and 50 ongoing clinical studies [3][9] - The company has seen a significant increase in innovative drug revenue, projected to exceed 10 billion RMB in 2025, accounting for over 80% of total revenue [3][17] - The oncology segment is a key growth driver, with revenue expected to reach 8.12 billion RMB in 2024, representing 66% of total revenue [27] Summary by Sections 1. Company Overview - Established in 1995, Hansoh Pharma has over 30 years of experience in the pharmaceutical industry, with a focus on R&D, production, and commercialization [9][10] - The company has a strong global management team with extensive industry experience [13][14] 2. Oncology Segment - The oncology segment is well-established, with a comprehensive product system covering various disease types and treatment stages [4][27] - The core product, Amivantamab, has gained significant market share and is expected to continue driving growth [27][29] 3. Innovative Drug Pipeline - The company has a diverse pipeline with over 40 innovative drug candidates across various therapeutic areas, including ADCs and dual antibodies [20][24] - Recent collaborations with multinational corporations have strengthened the company's R&D capabilities and expanded its pipeline [5][25] 4. Financial Projections - Revenue projections for FY25-27 are 13.76 billion RMB, 14.86 billion RMB, and 16.5 billion RMB, respectively, with net profits of 4.62 billion RMB, 4.69 billion RMB, and 5.2 billion RMB [6][17] - The company has increased its R&D investment significantly, with a projected R&D expense ratio of 22% in 2024 [15][17] 5. Market Position and Strategy - Hansoh Pharma is positioned as a leading player in the Chinese pharmaceutical market, with a focus on innovative drug development and international expansion [3][9] - The company aims to leverage its strong R&D capabilities and strategic partnerships to enhance its market presence and drive future growth [5][20]

Core Insights - The pharmaceutical-themed funds are dominating the performance rankings for the first half of the year, with nine out of the top ten funds being pharmaceutical-focused, led by Huatai-PineBridge Hong Kong Advantage Select A, which achieved a 103.67% return [1][2] - The strong performance of these funds is driven by multiple factors, including breakthroughs in innovative drug development, recovery of liquidity in the Hong Kong stock market, and restructuring of valuation systems through cross-border business development transactions [1][2] Fund Performance - The average return of the top ten actively managed equity funds exceeds 69%, with notable performances from Changcheng Pharmaceutical Industry Select A and Yongying Pharmaceutical Innovation Smart Select A, achieving returns of 87.73% and 79.79% respectively [2] - Huatai-PineBridge Hong Kong Advantage Select A is highlighted as a "doubling fund" for the year, marking a significant achievement in the market [2] Market Dynamics - The pharmaceutical sector is experiencing a "double hit" in profitability and valuation in 2025, with the Hang Seng Hong Kong Stock Connect Innovative Drug Index showing a year-to-date increase of 70.09% [3] - The performance of pharmaceutical funds is significantly influenced by their exposure to Hong Kong stocks, with the Hang Seng Healthcare Index rising by 54.59%, outperforming the A-share innovative drug index, which increased by 24.15% [3] Investment Strategy - Huatai-PineBridge Hong Kong Advantage Select A has benefited from investments in leading companies in the Hong Kong innovative drug and medical device sectors, capitalizing on improved overseas liquidity and favorable industry policies [4] - The introduction of financing channels for unprofitable biotech companies in Hong Kong has allowed competitive biotech firms to enter the market, with many now in advanced stages of research and commercialization [4] Future Outlook - The pharmaceutical industry is expected to maintain long-term investment value driven by demographic aging, consumption upgrades, and technological innovation, although caution is advised regarding potential overvaluation of certain stocks [6] - The current market for innovative drugs is characterized by high valuations and volatility, with expectations for a rebalancing between these factors in the near future [6][7] - The valuation of leading companies and key stocks is anticipated to be reassessed, with a focus on the long-term potential of authorized products and revenue realization from commercial partnerships [7]

Investment Rating - The report maintains a strong confidence in the pharmaceutical sector's potential for a reversal in 2025, highlighting innovative drugs and left-side sector recovery as the main investment opportunities [4][44]. Core Insights - The innovative drug sector remains in a high prosperity state, with significant collaborations continuing to emerge. The upcoming 85th American Diabetes Association (ADA) Scientific Sessions in June 2025 is expected to provide important clinical and research updates from endocrine and metabolic drug companies, suggesting investment opportunities in this area [11][44]. - The report emphasizes the increasing approval and quality of new drugs in China, indicating a recovery in the innovative drug sector that has been undervalued for several years. The global recognition of China's technological capabilities is also drawing renewed attention from capital markets towards domestic pharmaceutical companies [27][44]. - The report suggests focusing on leading companies with international expansion and innovation progress, such as Heng Rui Medicine, BeiGene, Innovent Biologics, and others, as well as ADC leaders like Keren Pharmaceutical and Bai Li Tianheng [27][44]. Summary by Sections Pharmaceutical Sector - UroGen Pharma's FDA approval of Zusduri, the first and only drug for treating recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, marks a significant breakthrough in drug delivery systems [20][21]. - The report highlights the progress in chronic disease metabolism, with Eli Lilly's oral Lp(a) lowering drug being considered for breakthrough therapy designation, indicating a growing pipeline of innovative treatments [23][27]. - Merck's oral PCSK9 inhibitor Enlicitide has shown positive results in Phase III trials, representing a significant advancement in cholesterol management therapies [28][29]. Medical Devices - The launch of the MAGLUMI X10, a high-speed automated chemiluminescence immunoassay analyzer, reflects the increasing demand for innovative medical devices in China [33][35]. - The investment by Xianjian Technology in Jianhu Medical to develop electrophysiology products indicates a strategic move to enhance capabilities in high-end medical devices [36][38]. Medical Services - The successful initiation of China's first invasive brain-computer interface clinical trial signifies a major advancement in medical technology, with potential applications for improving the quality of life for patients with spinal cord injuries and amputations [39][40]. - The report anticipates rapid growth in related industries, including high-end imaging equipment and surgical robots, driven by technological advancements and policy support [40]. Traditional Chinese Medicine - The approval of Fangsheng Pharmaceutical's innovative traditional Chinese medicine product marks a significant step in the development of new drugs in this sector, with an expected increase in new drug applications in the coming years [41][43].

Investment Rating - The investment rating for the pharmaceutical industry is "Positive" (maintained) [4][54]. Core Viewpoints - The report highlights that the AD (Alzheimer's Disease) treatment sector is expected to see significant advancements, with a recommendation to focus on companies like Tonghua Jinma and Dongcheng Pharmaceutical [3][9]. - The report emphasizes the importance of innovation, international expansion, and the aging population as key themes driving the industry forward [22][43]. - The pharmaceutical index has shown a positive performance, with a 1.40% increase from June 9 to June 13, outperforming the CSI 300 index by 1.66% [5][22]. Summary by Sections 1. AD Treatment Developments - The report notes that Alzheimer's Disease (AD) is a major global health challenge, with 51.62 million cases worldwide in 2019, including 13.14 million in China [9][10]. - The innovative oral drug, Succinyl-8-hydroxy-aminoguanidine, developed by Tonghua Jinma, has shown promising results in clinical trials and is expected to be a significant player in the AD treatment market [5][21]. 2. Industry Perspectives - The report indicates that the pharmaceutical sector is transitioning from traditional growth drivers to innovative solutions, with a focus on domestic innovation and international market expansion [22][43]. - The aging population is driving demand for chronic disease treatments, and the report suggests that the healthcare payment system is evolving to support this growth [41][43]. 3. Market Performance - The report provides a detailed analysis of stock performance, noting that 218 stocks increased in value while 263 decreased during the reporting period [5][22]. - Specific stocks such as Yiming Pharmaceutical and Sai Sheng Pharmaceutical have shown significant gains, while others like Renmin Tongtai have experienced notable declines [25][26]. 4. Investment Recommendations - The report recommends focusing on innovative pharmaceutical companies and those with strong international expansion capabilities, such as Heng Rui Pharmaceutical and Keren Pharmaceutical [43][44]. - It also highlights the importance of investing in sectors related to aging and outpatient consumption, suggesting companies like Kunming Pharmaceutical and Yuyue Medical [44].

红星资本局6月15日消息，创新药板块持续演绎下，已有公募基金产品年内收益率超过100%。 截至6月13日收盘，汇添富旗下重仓港股创新药的汇添富香港优势精选，年内总收益达到103.67%，暂时位居基金业绩榜首。据wind统计，距离A股上半年收 官还剩半个月时间，把握住创新药行情的多只基金，年内业绩已经大幅跑赢其他赛道产品。 红星资本局注意到，随着创新药基金"霸屏"收益榜，一则"电子研究群也在聊创新药"的消息引发热议，不少投资者也在社交平台询问"还能上车吗？"对此， 基金经理内部也有不同观点。 医药主题基金"苦尽甘来" 年内首只"翻倍基"出炉 今年以来，历经四年深度调整的医药板块迎来曙光，不少医药主题基金表现亮眼。红星资本局根据wind数据不完全统计发现，截至6月13日，260只（仅计算 初始基金，下同）名称中带有"医"或"药"的基金中，228只年内取得正收益，占比为87.69%，有88只收益率超过30%，63只收益率过40%。 其中，创新药主题基金不仅领涨整个医药板块，而且领涨市场。6月13日晚公布的基金净值数据显示，由张韡管理的汇添富香港优势精选QDII基金，年内收 益率达到103.67%，成为年内首只"翻倍 ...